D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.2B |
| 2 |
NVIDIA
NVDA
|
+$1.02B |
| 3 |
T-Mobile US
TMUS
|
+$911M |
| 4 |
Netflix
NFLX
|
+$699M |
| 5 |
Micron Technology
MU
|
+$672M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$768M |
| 2 |
Robinhood
HOOD
|
+$643M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$534M |
| 4 |
Microsoft
MSFT
|
+$493M |
| 5 |
Intuit
INTU
|
+$472M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.33% |
| 2 | Healthcare | 8.66% |
| 3 | Consumer Discretionary | 8.33% |
| 4 | Financials | 6.44% |
| 5 | Industrials | 6.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3251
International Paper
IP
$22.5B
| $818K | ﹤0.01% |
17,467
-1,207,479
| -99% | -$57.1M |
|
3252
Krispy Kreme
DNUT
$562M
| $818K | ﹤0.01% |
281,038
+64,973
| +30% | +$227K |
|
3253
Mesa Laboratories
MLAB
$540M
| $816K | ﹤0.01% |
+8,665
| New | +$951K |
|
3254
CALL
Macy's
M
$6.57B
| $816K | ﹤0.01% |
70,000
| – | – |
|
3255
Ligand Pharmaceuticals
LGND
$5.96B
| $813K | ﹤0.01% |
+7,151
| New | +$764K |
|
3256
Kura Oncology
KURA
$901M
| $812K | ﹤0.01% |
140,713
-278,275
| -66% | -$1.7M |
|
3257
Build-A-Bear
BBW
$428M
| $810K | ﹤0.01% |
15,719
-13,881
| -47% | -$588K |
|
|
SEE
3258
DELISTED
Sealed Air
SEE
| $804K | ﹤0.01% |
+25,926
| New | +$771K |
|
3259
Descartes Systems
DSGX
$6.09B
| $803K | ﹤0.01% |
7,900
+1,300
| +20% | +$137K |
|
3260
iShares Russell 2500 ETF
SMMD
$3.57B
| $803K | ﹤0.01% |
11,853
| – | – |
|
3261
PUT
Northern Oil and Gas
NOG
$2.21B
| $802K | ﹤0.01% |
28,300
-31,400
| -53% | -$845K |
|
3262
Synaptics
SYNA
$4.55B
| $802K | ﹤0.01% |
12,375
-37,940
| -75% | -$2.23M |
|
3263
PUT
Helmerich & Payne
HP
$3.36B
| $802K | ﹤0.01% |
52,900
+39,300
| +289% | +$720K |
|
3264
Praxis Precision Medicines
PRAX
$8.8B
| $801K | ﹤0.01% |
19,056
+6,848
| +56% | +$261K |
|
3265
Lattice Semiconductor
LSCC
$16.8B
| $801K | ﹤0.01% |
16,349
+9,398
| +135% | +$450K |
|
3266
CALL
Cogent Communications
CCOI
$612M
| $800K | ﹤0.01% |
+16,600
| New | +$843K |
|
3267
Gorman-Rupp
GRC
$2.13B
| $800K | ﹤0.01% |
21,790
+10,030
| +85% | +$361K |
|
3268
Centuri Holdings
CTRI
$2.76B
| $800K | ﹤0.01% |
+35,648
| New | +$697K |
|
3269
Akebia Therapeutics
AKBA
$343M
| $797K | ﹤0.01% |
219,089
+145,928
| +199% | +$401K |
|
|
BKHA
3270
Black Hawk Acquisition Corp
BKHA
$50.3M
| $797K | ﹤0.01% |
75,000
| – | – |
|
3271
CALL
RXO
RXO
$3.98B
| $797K | ﹤0.01% |
+50,700
| New | +$769K |
|
3272
Bio-Rad Laboratories Class A
BIO
$8.47B
| $796K | ﹤0.01% |
3,300
-15,625
| -83% | -$3.69M |
|
3273
iShares JPMorgan EM Corporate Bond ETF
CEMB
$398M
| $794K | ﹤0.01% |
+17,471
| New | +$780K |
|
|
NPKI
3274
NPK International
NPKI
$1.19B
| $793K | ﹤0.01% |
93,220
+10,461
| +13% | +$76.7K |
|
3275
Madison Square Garden
MSGS
$9.57B
| $793K | ﹤0.01% |
3,796
-25,484
| -87% | -$4.91M |
|
Similar funds
D.E. Shaw & Co's Q2 2025 Portfolio in Review
As of Q2 2025, D.E. Shaw & Co held 4,838 positions worth $141B, up 26% from $112B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
D.E. Shaw & Co deployed $7.51B of net new capital in Q2 2025, opening 647 new positions and adding to 1,556 existing holdings. Its largest new stake was Sea Limited: 1,365,221 shares worth $218M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was GE Vernova, an estimated $768M trimmed.
- D.E. Shaw & Co's largest Q2 2025 buy was Sea Limited: 1,365,221 shares worth $218M.
- D.E. Shaw & Co added most to Apple in Q2 2025, an estimated $1.2B increase.
- D.E. Shaw & Co's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $768M.
- D.E. Shaw & Co fully exited Novo Nordisk in Q2 2025, selling an estimated $176M.
- D.E. Shaw & Co's ten largest holdings make up 12% of its $141B portfolio in Q2 2025.
- D.E. Shaw & Co opened 647 new positions and closed 532 in Q2 2025.
- D.E. Shaw & Co's portfolio value rose 26% quarter-over-quarter to $141B.
Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.